5-HT3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial

Introduction: Patients with schizophrenia characteristically exhibit cognitive deficits. The level of cognitive impairment is found to predict the functional outcome of the illness more strongly than the severity of positive or negative symptoms. The purpose of this study was to assess the...

Full description

Bibliographic Details
Main Authors: Neyousha Mohammadi, Maryam Noroozian, Naregs Karamghadiri, Shahin Akhondzadeh
Format: Article
Language:English
Published: Iran University of Medical Sciences 2010-01-01
Series:Basic and Clinical Neuroscience
Subjects:
Online Access:http://bcn.iums.ac.ir/browse.php?a_code=A-10-1-19&slc_lang=en&sid=1